SHARE
COPY LINK

MONOPOLY

Goverment sacks board of pharmacy monopoly

Sweden’s government is set to replace the board of directors of the Apoteket AB pharmacy monopoly because the current board won’t accept the government’s rules for deregulation.

Goverment sacks board of pharmacy monopoly

At issue is the ownership directive put forward by Apoteket Omstrukturering AB, the parent company to Apoteket AB.

Health minister Göran Hägglund said that there is a difference of opinion between the board of the parent company and Apoteket AB.

“There have been different views between these boards, which isn’t so strange when you consider that there are a number of different issues to address, and that in some situations there can be different assessments and different conclusions. For my part, I don’t think there is any reason to make any more assessments than those already carried out by the restructuring company,” Hägglund told the TT news agency.

While the minister stopped short of saying that the government was firing the board of Apoteket AB, he didn’t deny that was the case.

“I wouldn’t be surprised by that headline even if I haven’t expressed myself that way,” he said.

Discussions between the board of the parent company and that of Apoteket AB have been ongoing since the summer. The Apoteket AB board learned of the new ownership directive last Friday.

“We’ve said no to the directive. We have objected in the sense that we refused to follow the instructions and directive we received. That’s the situation in reality,” said Apoteket AB board chair Per Båtelson to TT.

According to Båtelson, the board was unanimous in its view. He explained that the board had certain misgivings about how the directive treated the competition.

“I think it benefits our competitors in a way that is clearly iffy. It means micromanaging and putting limits on the company’s future growth which we can’t stand behind. The way they want to lock us in now would leave the company behind to such an extent that we won’t accept or be a part of it,” said Båtelson.

One of the measures affected by the proposed directive is Apoteket’s plans to have the Ica grocery store chain carry some of its products.

“We’ve had a planned partnership with Ica, which I can say now is more or less dead because we’re locked in until sometime into 2011 and Ica can’t wait so long,” said Båtelson.

A new board of directors for Apoteket AB will be chosen at an extra shareholders’ meeting to be held sometime in the near future.

The CEO of Apoteket, Stefan Carlsson, will remain at his post.

Apoteket Omstrukturering AB is owned by the state, with the health and social ministry acting as the principle owner.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

MEDICINE

Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report

Norwegian hepatitis C patients are waiting longer than they should for medical treatment due in part to a monopoly on its supply, according to a report.

Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report
Photo: SimpleFoto/Depositphotos

Between 15,000 and 20,000 Norwegians live with the chronic condition, which is treated with a 12-week course of medicine.

The cost of a 12-week course of the Epclusa medicine in Norway is 540,000 kroner (57,000 euros), according to the Klassekampen newspaper.

American pharmaceutical company Gilead Sciences owns a monopoly on supply of the medicine in the Scandinavian country, according to the report.

The medicine, which can cure the disease, is not prescribed to patients with the type 2 and 3 forms of hepatitis C – around 60 percent of sufferers in Norway – until their livers show clear signs of damage.

Although it can take many years from contracting the disease until the liver starts to fail, patients not given the treatment sooner are left with uncertain physical consequences as well as the psychological distress of living with the infectious condition, writes Klassekampen.

People with hepatitis C are not automatically entitled to the treatment, but are given it once symptoms are present.

Ronny Bjørnestad, head of NGO Prolar, which works to improve understanding of the illness, told Klassekampen that he had decided to obtain the treatment by going abroad.

“I felt I couldn’t wait any longer. I have a ticking bomb in my liver and am still infectious. I have a teenager in my house and it wouldn’t take any more than him accidentally using my razor blade for an accident to happen,” he told Klassekampen.

Bjørnestad said that he had purchased the same medicine for the equivalent of 7,500 kroner (800 euros) in Bangladesh, and then had it sent on to a friend in Scotland.

It is legal for Bjørnestad to bring the medicine back to Norway provided he begins the course of treatment while in Scotland, writes Klassekampen.

“If it was an illness that [mainly] affected a group with stronger resources then this would never have been accepted,” he told the newspaper.

The disease has relatively high prevalence amongst former and active drug addicts.

Olav Dalgard, consultant at the department of infectious diseases at Akershus University Hospital, told Klassekampen that the price of Hepatitis C medicine in Norway is “amorally” high.

“If we had cheaper medicine, we would recommend treatment of far more people at a much earlier stage. It would reduce the risk of disease spread. But prices must be reduced for that to be possible” Dalgard told Klassekampen.

The newspaper has contacted Gilead Sciences for comment. 

READ ALSO: 'More Norwegians than ever' take medication